Background-The coronary artery calcium (CAC) score predicts coronary heart disease (CHD) events, but methods for interpreting the score in combination with conventional CHD risk factors have not been established. Methods and Results-We analyzed CAC scores and CHD risk factor measurements from 6757 black, Chinese, Hispanic, and white men and women aged 45 to 84 years in the Multi-Ethnic Study of Atherosclerosis (MESA). CAC was associated with age, sex, race/ethnicity, and all conventional CHD risk factors. Multivariable models using these factors predicted the presence of CAC (C statistic=0.789) and degree of elevation (16% of variation explained) and can be used to update a "pretest" CHD risk estimate, such as the 10-year Framingham Risk Score, that is based on an individual's conventional risk factors. In scenarios in which a high CAC score is expected, a moderately elevated CAC score of 50 is reassuring (eg, reducing risk from 10% to 6% in a healthy older white man), but when a low/zero CAC score is expected, even with identical pretest CHD risk, the same CAC score of 50 may be alarmingly high (eg, increasing risk from 10% to 20% in a middle-aged black woman with multiple risk factors). Both the magnitude and direction of the shift in risk varied markedly with pretest CHD risk and with the pattern of risk factors. 
C oronary artery calcium (CAC) testing may be useful for guiding interventions to prevent coronary heart disease (CHD). 1 CAC scores predict risk for CHD events, 2 and higher -risk individuals are more likely to benefit from prevention interventions such as aspirin and statins. 3 It is not always clear, however, how clinicians should integrate information from the CAC score with what they already know about a patient's CHD risk and other characteristics.
Clinical Perspective on p 1084
Prior studies have demonstrated strong associations between CAC and a patient's age and sex, 4, 5 race/ethnicity, 5 and other CHD risk factors such as smoking, blood pressure, diabetes mellitus, and cholesterol. 6, 7 Given these associations, these individual characteristics should influence what CAC score a clinician expects when he or she orders the test in clinical practice. When the actual score is higher than expected, estimates of CHD risk should logically be revised upward for that patient, and vice versa when the actual score is lower than expected. How the clinician interprets the CAC score and estimates the "posttest" CHD risk, therefore, should depend both on the "pretest" risk 8 and on a careful analysis of the expected CAC score (ie, the "prevalence" 9 of CAC) in that patient, but methods for integrating risk information from the CAC score with conventional CHD risk factors have not been established. One previous analysis described expected CAC score distributions and relevant methods but used a convenience sample of clinic patients of unknown race/ethnicity who were referred or self-referred for CAC testing, and only self-reported risk factor data were available. 7 The Multi-Ethnic Study of Atherosclerosis (MESA) provides an ideal opportunity to examine CAC score distributions in a multiethnic community-based sample of research participants who have also undergone careful measurement of conventional CHD risk factors. Previous analyses of this data set have yielded widely referenced estimates of the value of
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the CAC score in terms of predicting future clinical events.
2,10
We used results from the baseline MESA examination to estimate associations between the CAC score and conventional CHD risk factors and produce methods for (1) estimating how likely different CAC scores are in a given clinical scenario and (2) combining the information from the CAC score with the patient's characteristics and a pretest risk estimate to obtain an integrated posttest estimate of CHD risk.
Methods

Study Sample
MESA is a prospective cohort study of 6814 people aged 45 to 84 years without known cardiovascular disease at baseline. Participants were recruited from 6 US cities from July 2000 through September 2002 and identified themselves as white (38%), black (28%), Hispanic (22%), or Chinese (12%) at the time of enrollment. The study was approved by the institutional review boards of each site, and all participants gave written informed consent. The study design has been described in detail elsewhere. 11 The present analysis uses only crosssectional data from the MESA baseline examination.
CAC Score
Carr et al 12 reported the details of the MESA computed tomography (CT) scanning and interpretation methods. Scanning centers assessed coronary calcium by chest CT with either a cardiac-gated electronbeam CT scanner (Chicago, IL, Los Angeles, CA, and New York, NY field centers) or a multidetector CT system (Baltimore, MD, Forsyth County, NC, and St Paul, MN field centers). Certified technologists scanned all participants twice over phantoms of known physical calcium concentration. A radiologist or cardiologist read all CT scans at a central reading center (Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, CA). We used the mean Agatston score for the 2 scans in all analyses. 13 Intraobserver and interobserver agreements were excellent (κ=0.93 and 0.90, respectively).
Conventional CHD Risk Factors
The primary predictors in our analysis were race/ethnicity and conventional CHD risk factors, including age, sex, blood pressure level and medication use, cholesterol (total and high-density lipoprotein), diabetes mellitus, and smoking status. These measurements were collected as part of the baseline examination. Blood pressure was measured 3 times with a Dinamap Pro 1000 automated oscillometric sphygmomanometer (Critikon, Tampa, FL) with the participant in a seated position; the mean of the last 2 blood pressure measurements was used. Total and high-density lipoprotein cholesterol, triglycerides, and plasma glucose were measured from blood samples obtained after a 12-hour fast. Diabetes mellitus was defined as a fasting plasma glucose level >126 mg/dL (7.8 mmol/L) or a history of medical treatment for diabetes mellitus.
We used the National Cholesterol Education Panel's Adult Treatment Panel III guidelines 3 version of the Framingham risk score (FRS) to estimate 10-year risk of CHD events using measurements obtained during the MESA research examination. For individuals with diabetes mellitus, we multiplied the FRS by 1.5 in men and by 1.8 in women, consistent with other published Framingham risk equations. 14 We used this score, without recalibration for race/ethnicity or otherwise, as the "pretest CHD risk" as recommended in current guidelines. 3 An alternate version of our analysis that used 5-year risk with recalibration for race/ethnicity using published data 15 is provided in the online-only Data Supplement.
Statistical Analysis
The CAC score distribution is highly skewed and is very frequently zero and hence is not amenable to a simple normalizing transformation, as noted by others. 16 After exclusion of zero values, the log-transformed CAC score is approximately normally distributed (Figure) .
This leads naturally to a 2-stage approach to modeling the CAC score distribution, with logistic regression (any CAC versus none) and then linear regression of the log-transformed CAC score among people with a nonzero score. This approach allows for parametric multivariable modeling of the CAC score distribution. As in previous analyses, 7 the 2-stage approach outperformed alternate 1-stage methods ( Figure I in the online-only Data Supplement).
After describing the study sample, we analyzed the expected distribution of the CAC score using the 2-step approach described above. We used 3 prespecified modeling approaches: (1) One that used the FRS as the only predictor; (2) one that used age and sex as the only predictors; and (3) one that tested a variety of models that considered age, sex/race/ethnicity, the conventional CHD risk factors used in the FRS, and diabetes mellitus. To refine our model without overfitting, we undertook an unbiased systematic model selection process with 10-fold cross-validation, 17 considering all possible models that included all the predictors, up to 2 pairwise interactions (0, 1, or 2), and up to 1 quadratic term (0 or 1) for each continuous variable. The top-performing models in terms of discrimination (cross-validated C statistic in the logistic regression model, rounded to 3 digits) were identified; among these, we chose the simplest for presentation. We then used the same predictors in the second step (linear regression) and present the 10-fold crossvalidated R 2 value as an optimism-corrected measure of model performance.
Using these models, we calculated the estimated prevalence of a CAC score in the ranges of 0, 1 to 100, 101 to 300, and >300. These categories (or similar ones) have been used in publications describing the value of the CAC score in terms of predicting future clinical events 2, 7, [18] [19] [20] and represent a simple and clinically important scheme for understanding the CAC score. The prevalence of scores in each of these categories is described according to clinical characteristics using the model parameters estimated as above.
As a final step, we used a simple algebraic calculation to combine risk information from conventional CHD risk factors with information from the CAC score. We assumed that the pretest risk (using the FRS 3 for this illustration) represented an average of people with different CAC scores, weighted by the probability of having a CAC score in each category (calculated according to modeling approach 3, described above). The risks in each category (annualized) were assumed to differ according to the adjusted relative risk estimates from Detrano et al 2 : CAC=0, reference; CAC=1 to 100, 3.61; CAC=101 to 300, 7.73; CAC >300: 9.67. With these assumptions, the posttest risk (using information from both the conventional risk factors and the CAC score) can be calculated algebraically. A variety of examples are presented, and an Excel-based calculator that can be used to estimate posttest risk in other clinical scenarios is published in the online-only Data Supplement.
Results
The MESA baseline examination included 6814 participants, all of whom had coronary calcium measured; 57 participants (<1%) were excluded because they were missing either total or high-density lipoprotein cholesterol, systolic blood pressure, diabetes mellitus, or smoking status, which left 6757 participants for the present analysis. Of these, 27% were black, 12% were Chinese, 22% were Hispanic, and 39% were non-Hispanic white; approximately half were women (52%). Clinically relevant differences were apparent across race/ethnicity in systolic blood pressure, diabetes mellitus, and smoking (Table 1) . Despite identical median FRSs across race/ ethnicity, the prevalence of CAC was significantly different (P<0.001), with the highest prevalence of CAC in non-Hispanic white participants. Age, sex, and race/ethnicity were all strong predictors of the presence and extent of CAC, and the distributions of log-transformed positive scores were approximately normal (Figure) . September 3, 2013
The FRS is a strong predictor of CAC (Table 2 , model 1). For each increase of 5% in the 10-year risk for CHD events, the odds of having a positive CAC score nearly doubled (odds ratio, 1.80; 95% confidence interval, 1.72-1.89) and the CAC score increased by 32% (95% confidence interval, 28%-36%) among people with CAC. The C statistic, a measure of how
Figure.
Distribution of coronary artery calcium (CAC) scores among men and women, on a logarithmic scale, by age and by race/ ethnicity. Categories chosen for histograms are evenly spaced on a logarithmic scale, corresponding to Ln(CAC) scores of <1, 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, and >8. The first bar represents subjects with no detectable CAC, which corresponds to an undefined Ln(CAC) value. A model that adjusted for age, sex, race/ethnicity, and conventional risk factors provided the best discrimination (crossvalidated C statistic-0.789) and explained the most variation in the CAC score (cross-validated R 2 =0.160; Table 2 , model 3). In a systematic model selection procedure, the model that used the individual predictor variables from the FRS (including an interaction between systolic blood pressure and use of blood pressure medications), as well as race/ethnicity and diabetes mellitus, performed as well or better than models that contained additional interactions or nonlinear terms for continuous variables (ie, no alternatives scored a C statistic >0.789). Even with adjustment for conventional CHD risk factors, race/ethnicity was a highly significant predictor of CAC; a similar model that did not include race/ethnicity did not perform as well (cross-validated C statistic=0.778, Table I in the online-only Data Supplement). Stratification by race/ethnicity (achieved by inclusion of all pairwise interactions for race/ethnicity with other predictors in the model) did not result in better performance (cross-validated C statistic=0.788); stratification by diabetes mellitus status or by sex led to similar results (cross-validated C statistic=0.787 and 0.788, respectively).
The predicted CAC distribution varied markedly by characteristics of the individual (Table 3 ). The expected distribution of CAC shifts toward higher scores with increasing FRS (Table 3 , panel 1) and even more so with male sex and higher age. For example, the probability of CAC=0 decreases from 89% in 45-year-old women to 6% in 85-year-old men (Table 3 , panel 2). The addition of race/ethnicity and use of the individual CHD risk factor measurements (instead of the BPmeds indicates blood pressure medications; CHD, coronary heart disease; CI, confidence interval; FRS, Framingham Risk Score; HDL, high-density lipoprotein; and SBP, systolic blood pressure.
*Additional model parameters used for estimating coronary calcium distribution (see Table 3 ) for models 1, 2, and 3 were the intercepts for logistic models on the logodds scale (-0.9649322, -6 .439981, and -7.900618, respectively), intercepts for the linear regression model (3.645373, -0.4340681, and -1.411425, respectively), and the standard deviation of the residuals for the linear model (1.747866, 1.701683, and 1.67148, respectively).
†The Framingham Risk Score, from the National Cholesterol Education Program's Adult Treatment Panel III guidelines, 3 with adjustment for diabetes mellitus status (see Methods).
‡Here, "white" refers to non-Hispanic European Americans. Table 3 , panel 3).
The interpretation of these CAC scores must also be individualized. By integrating the personalized CAC score prediction with the pretest risk, as from FRS, posttest risk estimates for each CAC score category can be obtained, and these differ sharply across scenarios (Table 4) . Although a CAC score of zero is generally reassuring (Table 4 , all examples), a very high CAC score increases posttest risk only a little when pretest risk is low (examples 1 and 2). Even more striking is the interpretation of an intermediate score (CAC=1-100), which is remarkably different across scenarios. For example, in a white man without CHD risk factors, a CAC score of 50 reassuringly reduces the posttest risk estimate (example 7), whereas in a 55-year-old Hispanic woman with many CHD risk factors, the same CAC score would predict an elevation in posttest risk (example 10). Even when pretest 10-year CHD CAC indicates coronary artery calcification; CHD, coronary heart disease; HDL, high-density lipoprotein; SBP, systolic blood pressure; and TC, total cholesterol. *All possible combinations of risk factors cannot be described here; only selected scenarios are presented. Results for other clinical scenarios can be calculated using the Excelbased calculator available in the online-only Data Supplement. Where the risk factor level is not specified, we used SBP=120 mm Hg, no blood pressure medications, TC=160 mg/dL, HDL=55 mg/dL, nonsmoker, nondiabetic. Pretest and posttest risk cannot be calculated for diabetics; see Methods.
†The Framingham Risk Score, from the National Cholesterol Education Program's Adult Treatment Panel III guidelines. 3 Framingham Risk Score estimates do not depend on race/ ethnicity; for an alternate analysis with recalibration for race/ethnicity, see the online-only Data Supplement. ‡Uses model parameters from Table 2 (model 3) and the 2-step estimation procedure described in Methods. Results are identical to the last panel of Table 3 . §Posttest risk estimates were calculated by assuming that the pretest 10-year CHD risk estimate represented an average of persons with different CAC scores, weighted by the probability of having a CAC score in each category. The risk in each category was calculated algebraically using these relative risk estimates from Detrano et al 2 : CAC=0, reference; CAC=1-100, 3.61; CAC=101-300, 7.73; and CAC >300, 9.67. Resulting risk scores were rounded to the nearest whole percentage. See Methods for details.
by guest on April 15, 2017 http://circ.ahajournals.org/ Downloaded from September 3, 2013 risk is held constant, such as at 10% (examples [5] [6] [7] , posttest risk varies markedly depending on the pattern of risk factors. In the elderly white man without risk factors who achieves his pretest risk of 10% by virtue of his age alone, even a high CAC score >100, or even >300, is quite likely and not overly worrisome (example 7), but in a black woman who achieves her pretest risk of 10% because of her adverse CHD risk factor profile, a CAC score >100 would be very rare, and a score between 1 and 100 would be alarmingly high (example 5). In a middle-aged Hispanic man with a CHD risk of 10%, a CAC of 1 to 100 changes pretest risk only slightly, whereas any CAC score >100 would be concerning (example 6). Note that in all of these "intermediate-risk" cases, the likelihood of obtaining a CAC score that might either reassure (posttest risk <5%) or raise concern (posttest risk >20%) is relatively high. In patients with high pretest risk (examples 10 and 11), the likelihood of obtaining a score that indicates a posttest risk ≤10%, which might decrease the urgency or aggressiveness of preventive therapies, is also moderately high. The Excelbased calculator provided in the online-only Data Supplement can be used to obtain these estimates for any given combination of risk factors.
Discussion
We show here that the distribution and interpretation of the CAC score is critically dependent on individual characteristics of the patient. Interpretation of the measured CAC score differs sharply in different clinical scenarios, even when the overall pretest CHD risk is similar. It is not enough to know that a patient is at intermediate risk; one must also have information about which risk factors led to that designation to interpret the CAC score. The methods and estimates provided here provide powerful "personalized" predictions that can help clinicians decide when to order a CAC scan and how to interpret the results to optimize targeting of CHD prevention interventions.
The present finding that CAC is related to conventional CHD risk factors is consistent with prior studies that consistently demonstrated associations between CAC and conventional risk factors, including age and sex, 4,5 as well as blood pressure, lipids, diabetes mellitus, and smoking. 6, 7 No prior studies have shown an association between blood pressure medication use and CAC, but this relationship is presumably mediated by past long-term exposure to higher average blood pressure, and prior studies have shown strong relationships between cumulative lifetime exposure to cardiovascular risk factors and CAC. 21, 22 The relationship with race/ethnicity has also been described. 5 Unlike prior studies that showed the general relationship between the overall FRS and CAC, 23 we demonstrate here that fitting the CAC score against the individual-component CHD risk factor measurements, along with race/ethnicity, provides more accurate CAC score predictions (even when subjected to cross-validation) than using the overall FRS without refitting the components. Our multivariable models provide estimates of the independent associations between risk factors and coronary calcium, as well as a more accurate method for estimating the expected distribution of CAC in any given clinical setting.
The findings are generally consistent with bayesian reasoning and risk reclassification theory, 1, 8, 24, 25 which suggest that CAC testing may be most useful for people who start out as having an intermediate risk for CHD. In the examples we provide, the likelihood of obtaining a CAC score that might change management (ie, pushing it outside of a putative "gray zone" between 5% and 20% 10-year risk) is highest in people with an intermediate pretest CHD risk (Table 4 , examples [5] [6] [7] , as well as 3-4 and 8-9) and is very low in people who are at very low pretest risk (examples [1] [2] . Prior analyses of MESA that focused on reclassification methodology provided empirical evidence for the relatively high reclassification rates we project in the present analyses. 10 The present analyses also project a relatively high rate of downward reclassification of risk among people who start off with high CHD risk (examples [10] [11] , consistent with prior reports of the high negative predictive value of a CAC score of 0. 8, 26, 27 Unlike prior studies, however, the present analysis highlights how important it is to personalize the interpretation of the CAC score. Although prior studies reported differences in posttest risk for different CAC scores, 2 they did not compare posttest risk with pretest risk. The present analyses show that posttest risk changes a different amount in different patients, and sometimes even in the opposite direction, as illustrated most clearly for a CAC score of 1 to 100 in Table 4 (examples 3, 5, and 8 versus 7, 9, and 11). The critical factor that determines how risk changes from pretest to posttest, as reported theoretically by prior investigators, 9 is how the actual test result compares with the expected test result in the individual patient (ie, the conditional "prevalence" 9 of that test result). Simply stated, a given test result (eg, CAC=50) may be either higher or lower than expected, and the risk estimate should logically shift higher or lower in accordance. By carefully defining the expected test result distribution for a patient, individualized with that patient's risk factor measurements, we can optimally personalize the interpretation of that patient's CAC score and quantify the expected shift from pretest to posttest in that patient.
No prior studies have presented methods for estimating the expected distribution of the CAC score in any given clinical setting that accounts for both demographic factors (including race/ethnicity) and carefully measured conventional CHD risk factors. The MESA Arterial Age Calculator 28 provides CHD risk estimates that use CAC, but they do not account for the strong correlations between risk factors (other than age) and CAC. In a prior publication, 7 we presented methods and results similar to what we present here, but that analysis used a convenience sample of patients referred in a clinical context (or self-referred) for a CAC score measurement, and the only information on conventional CHD risk factors was selfreported presence or absence (no continuous measurements). No race/ethnicity information was available. Unlike our prior report, the present results use high-quality measurements of CHD risk factors, take into account degree of elevation (eg, for blood pressure or cholesterol), and account for the strong effects of race/ethnicity.
The present analysis is subject to a number of important limitations. MESA is a community-based sample that includes 6 US cities across the country, but it is still possible that participants in the study were not perfectly representative of the US population. For example, research participants are known to be healthier on average than nonparticipants. Although measures of association are relatively robust to this type of selection pressure, the intercepts for our models (which determine overall average prevalence/score) might be subject to selection bias and lower than the average for the population.
Similarly, the FRS pretest CHD risk estimates used for illustration in Table 4 (and thus the corresponding posttest estimates in that same table) may not always be generalizable given that they were derived from the all-white Framingham study cohort. Methods and estimates required for recalibration have been published. 15 We used these methods to calculate recalibrated 5-year CHD risk scores for race-sex groups for which this is possible, and we present an alternate version of Table 4 in the online-only Data Supplement (Table II in the online-only Data Supplement; other results were unaffected). Other such substitutions are easily accomplished, and a userdefined pretest risk option is provided in the Excel calculator provided in the online-only Data Supplement.
Our method of using the CAC score together with conventional CHD risk factors (Table 4 ) depends on the assumption that the relative risk for CHD associated with different levels of CAC 2 is constant across different participant characteristics. For example, the relative risk of 7.73 for a person with a CAC score of 200 versus a CAC score of 0 is assumed to hold for both young healthy women and for older men with risk factors. Although there is evidence that CAC is very predictive across categories of race/ethnicity, 2 age, 29 and overall CHD risk, 30 systematic testing for and quantification of this type of interaction have not been conducted.
These results represent an attempt at producing a clinically relevant method for using the CAC score in clinical practice. The present results should help clinicians make the decision about when the test is likely to yield actionable results and how to interpret the CAC score in the light of the patient's individual risk profile based on his or her conventional CHD risk factors. The posttest risk estimate can then be used (in place of the pretest risk estimate) as a more personalized guide for how aggressive to be with interventions to prevent the onset of clinical CHD. The net comparative effectiveness and efficiency (cost-effectiveness) of this approach, however, have not been proven. To do so would require randomized, controlled trials of an integrated screening and targeted prevention strategy 31 or careful modeling of expected benefits, harms, and costs. Table 1 4) Supplemental Table 2 Each bar chart shows 1) The observed distribution of coronary artery calcium (CAC) scores, 2) The expected distribution of scores given the participants' coronary heart disease (CHD) risk factors using the two-stage modeling approach described in the Methods (Model 3), and 3) The expected distribution of scores given the same CHD risk factor predictors but using a one-stage modeling approach (linear regression with log(CAC+1) as the outcome). Four bar charts are provided, stratifying the MESA study population by level of CHD risk (10- Table 3 ) for Models 4 would be the intercept for the logistic models on the log-odds scale (-7 .98017), intercepts for the linear regression model (-1.44688 ) and the standard deviation of the residuals for the linear model (1.684672). 
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